Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.48 (transcriptase)
 9,479 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The major human tRNALys isoacceptors, tRNALys1,2 and tRNALys3, are selectively packaged into HIV-1 during assembly, where tRNALys3 acts as the primer for initiating reverse transcription. In this report, we shall review the evidence that supports a model for the formation of a tRNALys packaging complex, whose components include the precursor proteins Gag and Gag-Pol, viral genomic RNA, tRNALys, and lysyl-tRNA synthetase (LysRS). In the model proposed, the tRNALys packaging complex is formed when a Gag/Gag-Pol/viral RNA complex interacts with a tRNALys/LysRS complex, with Gag interacting with LysRS, and Gag-Pol interacting with tRNALys. The incorporation of Gag-Pol into HIV-1 requires its interaction with Gag multimers whose polymerization is promoted by RNA. Reverse transcriptase sequences within Gag-Pol also bind to tRNALys, and this binding is required for tRNALys packaging into viruses. LysRS, the enzyme that aminoacylates tRNALys, is also incorporated into HIV-1, and this protein is a strong candidate for being the signal that specifically targets tRNALys for viral incorporation. Newly-synthesized LysRS is a main source of viral LysRS, and its incorporation into viruses occurs via its interaction with Gag and independently of tRNALys packaging. While tRNALys incorporation into viruses depends upon its interaction with LysRS, tRNALys aminoacylation is not a requirement for viral packaging.
 ...
PMID:The tRNALys packaging complex in HIV-1. 1518 44

The non-structural protein 5B (NS5B) is an essential component for the genome replication of hepatitis C virus (HCV). Thus, its activity holds the potential of being a target for therapeutic actions against HCV. The availability of large amount of functionally active NS5B enzyme may facilitate the identification of NS5B inhibitors via high-throughput screening (HTS). Here, we expressed the C-terminal 20-amino acids truncated NS5B in a bacterial system using the N-terminal domain of Escherichia coli lysyl-tRNA synthetase (LysN) as a solubility enhancer. The fusion protein (LysN-NS5B) was purified in a yield of 6.2mg/L. The activity of LysN-NS5B was confirmed by in vitro RNA-dependent RNA polymerase (RdRp) activity assay, and the biochemical properties of LysN-NS5B were further characterized by kinetic analysis. The optimal RdRp activity was shown at 30 degrees C with 5mM of Mg(2+) or 10mM of Mn(2+), while the K(m) value for UTP was determined as 5microM. The RdRp activity of LysN-NS5B was strongly inhibited by phenyldiketoacid, a specific inhibitor of HCV NS5B activity. Our results suggest that the LysN fusion system is a suitable approach for producing an active form of NS5B that can be used for HTS of NS5B inhibitors.
 ...
PMID:Production and characterization of active hepatitis C virus RNA-dependent RNA polymerase. 2006 Apr 72

The leukodystrophies cause severe neurodevelopmental defects from birth and follow an incurable and progressive course that often leads to premature death. It has recently been reported that abnormalities in aminoacyl t-RNA synthetase (ARS) genes are linked to various unique leukodystrophies and leukoencephalopathies. Aminoacyl t-RNA synthetase proteins are fundamentally known as the first enzymes of translation, catalysing the conjugation of amino acids to cognate tRNAs for protein synthesis. It is known that certain aminoacyl t-RNA synthetase have multiple non-canonical roles in both transcription and translation, and their disruption results in varied and complicated phenotypes. We clinically and genetically studied seven patients (six male and one female; aged 2 to 12 years) from five unrelated families who all showed the same phenotypes of severe developmental delay or arrest (7/7), hypotonia (6/7), deafness (7/7) and inability to speak (6/7). The subjects further developed intractable epilepsy (7/7) and nystagmus (6/6) with increasing age. They demonstrated characteristic laboratory data, including increased lactate and/or pyruvate levels (7/7), and imaging findings (7/7), including calcification and abnormal signals in the white matter and pathological involvement (2/2) of the corticospinal tracts. Through whole-exome sequencing, we discovered genetic abnormalities in lysyl-tRNA synthetase (KARS). All patients harboured the variant [c.1786C>T, p.Leu596Phe] KARS isoform 1 ([c.1702C>T, p.Leu568Phe] of KARS isoform 2) either in the homozygous state or compound heterozygous state with the following KARS variants, [c.879+1G>A; c.1786C>T, p.Glu252_Glu293del; p.Leu596Phe] ([c.795+1G>A; c.1702C>T, p.Glu224_Glu255del; p.Leu568Phe]) and [c.650G>A; c.1786C>T, p.Gly217Asp; p.Leu596Phe] ([c.566G>A; c.1702C>T, p.Gly189Asp; p.Leu568Phe]). Moreover, similarly disrupted lysyl-tRNA synthetase (LysRS) proteins showed reduced enzymatic activities and abnormal CNSs in Xenopus embryos. Additionally, LysRS acts as a non-canonical inducer of the immune response and has transcriptional activity. We speculated that the complex functions of the abnormal LysRS proteins led to the severe phenotypes in our patients. These KARS pathological variants are novel, including the variant [c.1786C>T; p.Leu596Phe] (c.1702C>T; p.Leu568Phe) shared by all patients in the homozygous or compound-heterozygous state. This common position may play an important role in the development of severe progressive leukodystrophy. Further research is warranted to further elucidate this relationship and to investigate how specific mutated LysRS proteins function to understand the broad spectrum of KARS-related diseases.
 ...
PMID:Biallelic KARS pathogenic variants cause an early-onset progressive leukodystrophy. 3071 77